Smith Douglas Homesの空売り状況は、投資家がSmith Douglas Homesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Smith Douglas Homes (NYSE:SDHC) 株価情報, 空売り情報

Smith Douglas Homes

Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.

Smith Douglas Homes Corp. Class A Common Stock

Smith Douglas Homes Corp

Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) on Monday disclosed a strategic collaboration with Shenzhen&#8217;s largest taxi operator, Shenzhen Xihu Corporation Limited, to deploy a fleet of over 1,000 Pony.ai&#8217;s seventh-generation Robotaxis in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45716395/pony-ai-inc-reaches-strategic-partnership-with-xihu-group-for-robotaxi-deployment-in-shenzhen" rel="noreferrer noopener">Shenzhen in the coming years</a>.
This partnership utilizes an &#8216;asset-light + AI-empowered model&#8217; to integrate autonomous driving with local mobility networks, with the goal of supporting the deployment of intelligent mobility services to more passengers in China&#8217;s tier-one cities, the company said.
Xihu Group will focus on fleet and asset operations, safety and service guarantees, and benefit economically from the fleet and asset operations.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45612556" rel="noreferrer noopener">Tesla Autonomous Driving Rival Pony AI To Expand Robotaxi Fleet Into Dubai Following Agreement With Regulators</a>
Meanwhile, Pony.ai will concentrate on AI technology innovations and scalable Robotaxi dispatch and services, fostering a mutually beneficial outcome that accelerates large-scale development.
This partnership merges Xihu Group&#8217;s operational know-how with Pony.ai&#8217;s proprietary hardware/software, AI-powered dispatch, and deep understanding of user needs to deliver a seamless autonomous mobility experience.
Pony has been on a collaboration spree to boost expansion across the world.
Last week, Pony AI announced that it signed a memorandum of understanding with Dubai&#8217;s Roads and Transport Authority to deploy <a target="_blank" href="https://www.benzinga.com/news/global/25/05/45628748/pony-ai-stock-is-up-today-whats-going-on" rel="noreferrer noopener">driverless taxis in the region</a>.
Notably, the company already has licenses in the U.S., South Korea, China and Luxembourg, and has more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/05/45612556/tesla-autonomous-driving-rival-pony-ai-to-expand-robotaxi-fleet-into-dubai-following-agreement-with-regulators" rel="noreferrer noopener">270 robotaxis in its fleet</a> in China.
In May, the company confidentially filed for&nbsp;a Hong Kong initial public offering to help raise <a target="_blank" href="https://www.benzinga.com/25/05/45416148/pony-ai-shares-rise-after-report-of-confidential-hong-kong-ipo-to-fund-robotaxi-expansion" rel="noreferrer noopener">capital to expand its business</a>.
Investors can gain exposure to the stock via First Trust S-Network Electric &amp; Future Vehicle Ecosystem ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARZ#NASDAQ">CARZ</a>).
Price Action: PONY shares are trading higher by 4.36% to $20.10 premarket at last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45514486/chinas-pony-ai-robotaxi-revenue-jumps-200-eyes-1000-vehicle-fleet" target="_blank" rel="noreferrer noopener">China&#8217;s Pony AI Robotaxi Revenue Jumps 200%, Eyes 1,000-Vehicle Fleet</a></li>
</ul>
Image via Shutterstock

Asia

Equities

News

Movers

Tech

CARZ

PONY

Pony.ai, Xihu Group To Deploy Over 1,000 Robotaxis In Shenzhen

Femasys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share sold to certain existing institutional stockholders of Femasys and a price of $1.02 per share to certain of its directors and officers. The gross proceeds of the public offering and private placement to Femasys, before deducting the underwriting and placement agent discounts and commissions and other public offering and private placement expenses payable by Femasys, are expected to be approximately $4.5 million. Femasys intends to use the net proceeds from the public offering and the private placement for expansion of commercial efforts, development of its products and product candidates, general corporate purposes, capital expenditures, working capital and general and administrative expenses. In addition, Femasys has granted the underwriter a 30-day option to purchase up to an additional 540,000 shares of its common stock sold in the public offering. All of the securities are to be sold by the Company. The public offering and the private placement are expected to close on or about June 2, 2025, subject to satisfaction of customary closing conditions. The closing of the public offering is not contingent on the private placement, and the closing of the private placement is not contingent on the public offering.

FEMY

Femasys Prices 3.6M Share Public Offering At $0.85/Shr; Announces Private Placement Of 1.69M Shares At Up To $1.02/Shr

Truist Securities analyst Matthew Coad initiates coverage on Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Buy rating and announces Price Target of $181.

Price Target

Initiation

Analyst Ratings

Truist Securities Initiates Coverage On Fiserv with Buy Rating, Announces Price Target of $181

Intellinetics, Inc. ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fir.intellinetics.com%2F&amp;,%20esheet=54262142&amp;,%20newsitemid=20250602527259&amp;,%20lan=en-US&amp;,%20anchor=NYSE+American%3A+INLX&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">INLX</a>), a digital transformation solutions provider, is pleased to announce that it has been awarded a five-year contract with a long-term customer for document scanning and micrographic conversions services worth up to an estimated aggregate $40 million in Total Contract Value (TCV). The revenue will be recognized as work is completed on projects spanning the contract period, which runs from June 1, 2025 through May 31, 2030 plus an optional five more extension years.
The contract, the largest in the company's history, was awarded following a competitive evaluation process. Specific standards and procedures for quality assurance, security, key personnel, and depth and breadth of service were assessed and scored to determine the vendor of choice. The $40 million TCV is based upon the customer's procurement budget, but subject to customer reduction or termination in its sole discretion during the contract period.

INLX

Intellinetics Lands $40M Deal, Largest in Company History, for Document Scanning Services

Apple&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) former designer and a key mind behind the first iPhone, Jony Ive says the hardest part of creativity isn't dreaming up lofty ideas, it&#8217;s having the nerve to drop most of them — a lesson he learnt from Steve Jobs.
What Happened: In a 2014 on-stage conversation with Vanity Fair editor Graydon Carter, Apple's then–design chief recalled the single lesson Steve Jobs drilled into him: relentless focus. "This sounds really simplistic, but it still shocks me how few people actually practice this," Ive told the New Establishment Summit crowd.
Jobs, whom Jony Ive called "the most remarkably focused person I've ever met," kept score with a blunt question: "How many things have you said no to?" Ive confessed he sometimes produced "sacrificial" examples — projects he never liked anyway, only to be caught. True focus, he explained, means saying no &#8220;to something that, with every bone in your body, you think is a phenomenal idea,&#8221; because it distracts from the mission at hand.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Jony Ive on what Steve Jobs taught him about focus" width="500" height="281" src="https://www.youtube.com/embed/EKBVLzOZyLw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
The clip has resurfaced online as a pocket-sized master class in priority-setting, racking up millions of impressions on X and LinkedIn posts that repeat Ive's warning that focus is an "every-minute" discipline, not a Monday-morning resolution.
See also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45716400/pharma-bro-martin-shkreli-sees-10-trillion-potential-in-palantir-but-cautions-one-bad-quarter-and-its-down-50">&#8216;Pharma Bro&#8217; Martin Shkreli Sees $10 Trillion Potential In Palantir, But Cautions: &#8216;One Bad Quarter And It&#8217;s Down 50%&#8217;</a>
The mantra helps explain why Apple routinely axed promising prototypes, an approach former Wall Street Journal editor Walter Isaacson says let Jobs spend &#8220;<a href="https://www.benzinga.com/general/24/04/38403093/steve-jobs-spent-hour-after-hour-on-product-design-he-cared-about-god-being-in-the-details-says-walt">hour after hour</a>&#8221; on seemingly the smallest bits of product design that made products iconic.
Why It Matters: Other CEOs have since borrowed the mantra. Salesforce's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) Marc Benioff credits a <a href="https://www.benzinga.com/25/05/45559653/steve-jobs-once-invited-marc-benioff-to-his-office-with-two-ipads-in-2010-the-lesson-that-shaped-a-270-billion-salesforce-empire">2010 chat with Jobs</a> for sharpening his own product discipline. Disney's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) Bob Iger received a different kind of counsel as Jobs urged him to <a href="https://www.benzinga.com/news/24/09/40787212/steve-jobs-urged-bob-iger-to-retire-and-enjoy-life-before-its-too-late-heres-how-that-advice-shaped">retire and enjoy life</a> before it's too late, advice the executive says still frames how he paces his tenure at the entertainment giant.
Apple&#8217;s chief Tim Cook recalls that <a href="https://www.benzinga.com/24/11/42090539/tim-cook-goes-from-small-town-to-ceo-of-worlds-largest-company-why-he-believes-in-asking-lots-of-questions">Jobs&#8217; parting words</a>, shared the night before his death, were simply to do what he thought was right when it came to leading Apple.
Snowflake&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) Frank Slootman had his own key takeaway from Jobs&#8217; management philosophies. Slootman believes the late Jobs always either found a product &#8220;insanely great&#8221; or &#8220;sh&#x2A;t&#8221; and that approach ensured there was never any <a href="https://www.benzinga.com/news/management/25/05/45604617/steve-jobs-wasnt-happy-unless-things-were-insanely-great-and-thats-why-this-tech-ceo-is-passionate-about-moving-mental-boundaries-that-withhold-pe">room for mediocrity</a> within the company&#8217;s walls.
Read next: <a href="https://www.benzinga.com/news/politics/25/06/45716936/speaker-mike-johnson-says-4-8-million-wont-lose-medicaid-unless-they-choose-to-do-so-calls-gop-cuts-an-important-and-frankly-heroic-thing">Speaker Mike Johnson Says 4.8 Million Won&#8217;t Lose Medicaid &#8216;Unless They Choose To Do So,&#8217; Calls GOP Cuts &#8216;An Important And Frankly Heroic Thing&#8217;</a>

General

AAPL

SNOW

Jony Ive Once Said Steve Jobs Demanded Everyone At Apple Often Answer This Question: 'It Still Shocks Me How Few People Actually Practice This'

South African Firm Commits to Driving American Industrial Renewal and Africa-U.S. Commercial Diplomacy
FISHERS, IN / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 2, 2025 / American Resources Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) ("American Resources"), through its holding in ReElement Technologies Corporation ("ReElement"), a leading U.S. innovator in rare earth element (REE) and critical mineral refining, announced today that Novare Holdings Proprietary Limited ("Novare"), a South African-headquartered institutional investment firm, has committed to be the anchor investor in ReElement's private capital raise. This commitment will help unlock approximately $150 million in combined equity and debt financing to expand ReElement's refining operations at its 42-acre Marion, Indiana supersite - revitalizing the former RCA-Thomson television factory, once a symbol of American industrial strength. ReElement is proud to revive the facility as a hub for advanced manufacturing, signaling the return of high-value industry to the American heartland.

AREC

American Resources Secures $150M Investment To Expand Rare Earth Refining

BriaCell Therapeutics Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ)), (TSX:<a href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical data in three clinical poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. BriaCell has featured robust survival and clinical benefit data from its Bria-IMT Phase 2 clinical study, clinical progress data from its ongoing pivotal Bria-IMT Phase 3 study (ClinicalTrials.gov identifier:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=790IRU9LzZ0Dxe4XexrZDEDviwlJpdgB-1C1QC9E2Vb8F-p7I7cPdraEg974je-7iVaUfa4gjc8h1nNbivVKFaYoKoMKOAHQnKcsQijafmsokbVa43Zf8L9JQ3y0zyD8">NCT06072612</a>), and Phase 1/2 study of Bria-OTS (ClinicalTrials.gov identifier:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=790IRU9LzZ0Dxe4XexrZDFfXNgbntwwBxg8-h8afaozqcUDEFcFxDyPAp_kKbs497Y7f3nFjOcvH7xEwpgK4Eg0mKY4_KJNHUSEa_5_qs1dW9vFRlmT2j4CdMeIXa0ahIr1-ffU-qalVCBxlUROrV88iHMsE1u7bAa90JoGSQydQiOtszLGcKkyrdp5oLBD3TOJOYWtuBZsbc2kX5Kir18CSFB1HLaXVA2orOo-ZHysYqaFYvUicAICItxvNRk4tkYMsuhcqUiGda_NeF5xiQbPb02L6lOVcygJpsyNuaM2fTKK1aaBcPbu0L--LgH72">NCT06471673</a>) in metastatic breast cancer.

BCTX

BriaCell Highlights Breast Cancer Trial Data at 2025 ASCO Annual Meeting

Biotech

Health Care

CNTX

Context Therapeutics Is Presenting A Trial In Progress Poster For The Phase 1 Trial Of CTIM-76 In Ovarian, Endometrial, And Testicular Cancers At The 2025 American Society Of Clinical Oncology Annual Meeting, Expect To Share Initial Data In The First Half Of 2026

Truist Securities analyst Matthew Coad initiates coverage on Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Hold rating and announces Price Target of $97.

FOUR

Truist Securities Initiates Coverage On Shift4 Payments with Hold Rating, Announces Price Target of $97

Truist Securities analyst Matthew Coad initiates coverage on Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) with a Hold rating and announces Price Target of $11.

LSPD

Truist Securities Initiates Coverage On Lightspeed Commerce with Hold Rating, Announces Price Target of $11

<ul>
<li>Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol.</li>
<li>INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.</li>
<li>Median PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two years &nbsp;</li>
</ul>

INAB

IN8Bio Announced New Long-term Clinical Data From Its Fully Enrolled Phase 1 Trial Of INB-200 In Patients With Newly Diagnosed Glioblastoma Multiforme, Demonstrating Prolonged Progression-Free Survival

<ul>
<li>ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissue</li>
<li>Study initiation highlights Arrowhead's leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM&#x2122;) platform</li>
<li>In preclinical studies, ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>
Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes.

ARWR

Arrowhead Pharma Doses First Subjects In Phase 1/2a Clinical Trial Of ARO-ALK7, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Obesity

Shares of Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) rose sharply in <a href="https://www.benzinga.com/quote/BPMC/news">today's pre-market trading</a>.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced plans to acquire Blueprint Medicines for $9.5 billion.
Blueprint Medicines shares jumped 26.9% to $128.62 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares jumped 199% to $14.74 in pre-market trading after the company reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 achieving statistically significant results for primary and key secondary endpoints in the treatment of Chronic Rhinosinusitis (CRS).</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) rose 93.2% to $4.81 in pre-market trading.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) surged 69% to $32.02 in pre-market trading after the company said Atacicept ORIGIN Phase 3 trial met primary endpoint of reduction in UPCR for IgAN treatment.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) jumped 68.5% to $0.47 in pre-market trading after gaining 13% on Friday.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) surged 51.4% to $9.20 in pre-market trading after jumping 485% on Friday.</li>
<li>Black Spade Acquisition II Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSII#NASDAQ">BSII</a>) gained 37.3% to $13.29 in pre-market trading after falling 5% on Friday.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) climbed 27.7% to $1.6990 in pre-market trading after jumping 24% on Friday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) rose 25.6% to $7.32 in pre-market trading.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) gained 14.1% to $109.32 in pre-market trading. BioNTech and Bristol Myers Squibb announced a global strategic partnership to co-develop and co-commercialize next-generation bispecific antibody candidate BNT327 broadly for multiple solid tumor types</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares dipped 23.2% to $3.77 in pre-market trading. ReShape Lifesciences entered into equity distribution agreement relating to sale of up to $9.7 million of shares of common stock.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 22.6% to $0.7500 in pre-market trading after the company announced suspension of Nasdaq trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) fell 20.2% to $0.8300 in pre-market trading after gaining 8% on Friday.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) declined 18.4% to $62.60 in pre-market trading after the company filed for mixed shelf offering.</li>
<li>ContextLogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares tumbled 18.3% to $6.70 in pre-market trading. ContextLogic will commence trading on the OTC Markets and delist from the Nasdaq.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) fell 17.9% to $0.8788 in pre-market trading after the company announced a proposed public offering.</li>
<li>Super League Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) fell 16.4% to $0.1629 in today's pre-market trading. Super League Enterprise, on Friday, announced a registered direct offering.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) dipped 16% to $1.68 in pre-market trading. TIAN RUIXIANG shares gained 8% on Friday after the company announced plans to buy Ucare for $150 million in an all-stock deal.</li>
<li>Lucid Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 15.1% to $1.18 in pre-market trading. Lucid Diagnostics may offer sell shares of common stock of up to $25 MILLION.</li>
<li>Algoma Steel Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) fell 9.2% to $4.78 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

ASTL

BMGL

BNAI

BNTX

BPMC

BSII

CLEU

FAAS

LOGC

LUCD

LYRA

RSLS

SBET

SLXN

TIRX

VERA

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket

During a town hall in Butler County on Friday, Sen. Joni Ernst (R-Iowa) brushed off a voter's warning about the <a href="https://www.benzinga.com/25/05/45558613/house-advances-trumps-sweeping-one-big-beautiful-bill-after-key-medicaid-tax-and-border-security-changes">effects of losing healthcare</a> with a reminder about collective mortality, drawing widespread criticism.
What Happened: Ernst was questioned about President Donald Trump's "big, beautiful bill", which includes major cuts to welfare programs like Medicaid, according <a href="https://www.washingtonpost.com/politics/2025/06/01/joni-ernst-medicaid-comments/">to</a> The Washington Post.
When a participant warned that <a href="https://www.benzinga.com/general/health-care/25/05/45344596/house-republicans-push-880-billion-medicaid-cuts-to-renew-trump-tax-breaks-democrat-warns-millions-will-lose-their-health-care">people could die if Medicaid coverage was taken away</a>, Ernst replied, "Well, we all are going to die." "So, for heaven's sakes. For heaven's sakes, folks," she added.
On Saturday, Ernst posted a 24-hour Instagram Story video that seemed to make fun of the criticism she received for her comments.
Filming from a cemetery, she said, "I made an incorrect assumption that everyone in the auditorium understood that, yes, we are all going to perish from this earth." "So I apologize, and I'm really, really glad that I did not have to bring up the subject of the tooth fairy as well," she added, ending the vide with a religious message: "For those that would like to see eternal and everlasting life, I encourage you to embrace my Lord and savior Jesus Christ."
See Also: <a href="https://www.benzinga.com/news/retail-sales/25/06/45712543/us-tariff-impact-prices-surge-at-walmart-and-target-employees-say-some-jumps-top-38">US Tariff Impact: Prices Surge At Walmart And Target, Employees Say—Some Jumps Top 38%</a>
Why It Matters: The bill at the center of the controversy is projected by the Congressional Budget Office to withdraw Medicaid coverage from 8.7 million people and raise the number of uninsured Americans by 7.6 million over the next ten years.
In Iowa, where one in five residents depends on Medicaid, including half of all nursing home occupants, the damage could be severe.
Democrats were quick to respond to Ernst's statements. "Everybody in that audience knows that they're going to die. They would just rather die in old age, at 85 or 90, instead of dying at 40," said Sen. Chris Murphy (D-Conn.) on CNN. "When rural hospitals close because of this bill… more people will die at a younger age."
"Joni Ernst said the quiet part out loud," said DNC chairman Ken Martin in a statement. "They don't care whether their own constituents live or die as long as the richest few get richer."
Meanwhile, Office of Management and Budget Director Russell Vought <a href="https://www.benzinga.com/news/politics/25/06/45717492/medicaid-cut-concerns-are-totally-ridiculous-says-trumps-budget-chief-russell-vought-quips-i-love-e">dismissed fears about Medicaid cuts</a> as "ridiculous," and Speaker Mike Johnson (R-La.) argued that those who lose Medicaid <a href="https://benzinga.com/node/45716936">will do so by personal choice</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/25/06/45712636/peter-lynch-we-are-not-saving-enough-money-thats-the-most-single-important-thing-people-have-to-do-they-have-to-save-some-more">Peter Lynch: &#8216;We Are Not Saving Enough Money, That&#8217;s The Most Single Important Thing People Have To Do, They Have To Save Some More&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Medicaid Cuts Backlash Grows As Sen. Joni Ernst Tells Voters 'Well, We All Are Going To Die,' Mocks Critics From A Cemetery

Sen. Elizabeth Warren (D-Mass.) expressed agreement with President Donald Trump on eliminating the federal debt ceiling while sharply criticizing proposed tax breaks for wealthy Americans amid escalating fiscal concerns.
What Happened: Warren shared a video of Trump&#8217;s remarks on her X account, stating: &#8220;Trump and I agree: the debt limit should be scrapped to prevent an economic catastrophe. Let&#8217;s pass a bipartisan bill and get rid of it forever. But jacking up the debt limit by $4 trillion to fund more tax breaks for billionaires is an outrage.&#8221;
In the video, Trump acknowledged Warren&#8217;s longstanding position, saying: &#8220;Elizabeth Warren and various other people would like to see that. Her whole career, she wanted to see it terminated, gotten rid of, not being voted on every five years or ten years. And the reason was because it&#8217;s so catastrophic for our country. And I always agreed with her.&#8221; 
Trump noted the debt ceiling&#8217;s automatic four-year extension in current legislation, calling potential defaults &#8220;too catastrophic.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> and I agree: the debt limit should be scrapped to prevent an economic catastrophe. Let&#39;s pass a bipartisan bill and get rid of it forever. But jacking up the debt limit by $4 trillion to fund more tax breaks for billionaires is an outrage. <a href="https://t.co/tMRdSsY5St">pic.twitter.com/tMRdSsY5St</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1928540597180076252?ref_src=twsrc%5Etfw">May 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45716400/pharma-bro-martin-shkreli-sees-10-trillion-potential-in-palantir-but-cautions-one-bad-quarter-and-its-down-50">&#8216;Pharma Bro&#8217; Martin Shkreli Sees $10 Trillion Potential In Palantir, But Cautions: &#8216;One Bad Quarter And It&#8217;s Down 50%&#8217;</a>
Why It Matters: Trump&#8217;s debt ceiling support connects to his &#8220;One Big, Beautiful Bill,&#8221; which passed the House 215-214 but faces Senate resistance. The legislation uses a four-year debt ceiling extension to enable $3.8 trillion in additional deficit spending, according to <a href="https://www.benzinga.com/news/25/05/45634863/gop-senators-threaten-to-block-trumps-tax-and-spending-bill-over-deficit-medicaid-cuts-and-debt-ceil">Congressional Budget Office estimates</a>.
Warren agrees on eliminating the debt ceiling permanently but opposes the current $4 trillion increase for what she calls billionaire tax breaks. Republican senators <a href="https://www.benzinga.com/news/25/05/45634863/gop-senators-threaten-to-block-trumps-tax-and-spending-bill-over-deficit-medicaid-cuts-and-debt-ceil">threaten to block the bill</a> over deficit concerns.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45716383/trump-administration-shuts-down-66-million-food-stamp-fraud-and-bribery-scheme-arrests-usda-employee-and-5-others">Trump Administration Shuts Down $66 Million Food Stamp Fraud And Bribery Scheme, Arrests USDA Employee And 5 Others</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Regulations

Economics

Elizabeth Warren Agrees With Trump On Scrapping Debt Limit—But Blasts $4 Trillion Hike For Billionaire Tax Breaks

Truist Securities analyst Matthew Coad initiates coverage on Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy rating and announces Price Target of $58.

AFRM

Truist Securities Initiates Coverage On Affirm Holdings with Buy Rating, Announces Price Target of $58

KYMR

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Truist Securities analyst Matthew Coad initiates coverage on PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Sell rating and announces Price Target of $68.

PYPL

Truist Securities Initiates Coverage On PayPal Holdings with Sell Rating, Announces Price Target of $68

Economist Lyn Alden warns that U.S. fiscal deficits are an unstoppable force, driving demand <a href="https://www.benzinga.com/25/05/45610847/bitcoins-setup-exact-same-like-golds-explosion-during-1970s-says-analyst-but-critics-have-something-to-add">for scarce assets</a> like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and gold.
What Happened: Speaking at Bitcoin conference 2025 last week, Alden popularized the phrase &#8220;nothing stops this train&#8221;—borrowed from the show Breaking Bad—to describe a fiscal trajectory that, in her view, is now governed by both mathematical inevitability and political intransigence.
"We're in a system where the brakes are gone," she <a href="https://www.youtube.com/watch?v=Giuzcd4oxIk">said</a>. "Raising interest rates only accelerates the federal deficit faster than it slows private borrowing."
Using historical data, Alden demonstrated how federal deficits used to rise during recessions and shrink during recoveries. 
That relationship broke down after 2017. Since then, unemployment has remained low while deficits have ballooned, reaching 6–7% of GDP outside of crisis periods.
"This is not just cyclical," she argued. "It's structural."
A major factor is demographics. 
As the Baby Boomer generation retires, Alden noted that Social Security's $3 trillion trust fund will be spent down, injecting more money into the economy while limiting political appetite for fiscal restraint. 
Also Read: <a href="https://www.benzinga.com/cannabis/25/05/45698521/bitcoin-drops-to-105000-after-trump-warns-hes-no-longer-mr-nice-guy">Bitcoin Drops To $105,000 After Trump Warns He&#8217;s &#8216;No Longer Mr. Nice Guy&#8217;</a>
"It's the third rail of U.S. politics," she said. "No party will touch it."
The result: long-term, unavoidable deficits that persist regardless of the business cycle or who wins elections.
Alden likened the system to a "shark that must keep swimming." 
Citing data from 110 years of debt history, she showed that total debt levels almost never decline. 
"The last time total U.S. debt dropped meaningfully was during the Great Depression and even in 2008, when it fell slightly, the Fed responded by ballooning the monetary base from $1 trillion to $6 trillion."
With U.S. debt now exceeding 100% of GDP and interest rates no longer structurally declining, Alden warned that interest expenses are consuming a rising share of federal outlays. 
"We're in Wonderland," she said. "The tools that worked for decades now operate in reverse."
What&#8217;s Next: In contrast to fiat's "flexible ledger," Alden positioned Bitcoin as a fundamentally different system: one based on absolute scarcity, transparency, and a fixed supply.
"The fiat system always falls back on printing more units," she said. "Bitcoin doesn't allow that."
Her conclusion: The only rational hedge against this unsustainable trajectory is to hold "the highest quality scarce assets, "chief among them, Bitcoin.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45697994/robinhood-ceo-says-political-infighting-is-a-concern-for-crypto-legislation">Robinhood CEO Says Political Infighting Is &#8216;A Concern&#8217; For Crypto Legislation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

'Nothing Stops This Train': US Fiscal Deficits Drive Bitcoin's Case As A Hedge, Says Lyn Alden

Truist Securities analyst Matthew Coad initiates coverage on Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Sell rating and announces Price Target of $31.

Comments

Smith Douglas Homes

空売り

Smith Douglas Homes (NYSE:SDHC) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル